Silence Therapeutics (SLN): Collaboration-heavy RNAi company with milestone-driven economics

Silence Therapeutics discovers and develops siRNA therapeutics and monetizes primarily through out-licenses, milestone receipts, and royalties rather than product sales. The business model is partnership-centric: the firm advances discovery and early development and then captures value through exclusive licenses and milestone schedules, with occasional royalty streams on partner product sales. For investors, the company is a high-leverage, event-driven biotech where cash flow is driven by discrete collaboration outcomes rather than steady commercial revenue.
For a rapid view of partner and customer exposures, visit https://nullexposure.com/.

How Silence operates and why that matters to investors

Silence runs a classical biotech partnering strategy: internal discovery via its GOLD siRNA platform and then commercial monetization through licensing deals and development collaborations. This creates several structural characteristics you should treat as part of the investment thesis:

• Contracting posture: licensing and milestone structures dominate. Contracts typically transfer development responsibilities and grant rights to partners in return for upfront cash, staged milestones and royalties on future sales.
• Revenue concentration and lumpy timing. Collaboration receipts and milestone accounting produce large, irregular inflows; FY2024 and FY2025 revenue trends demonstrate sharp swings tied to the completion or conclusion of partner programs.
• Global commercialization orientation. Agreements allocate rights on a worldwide basis or carve out regional rights, enabling partners to pursue global development and commercialization.
• Maturity and termination risk embedded in past deals. The company has completed obligations under multiple collaborations, producing both one-time catch-ups and terminations that change future revenue profiles.

These features make Silence a company where partner execution and milestone delivery dominate near-term valuation, while platform value underpins longer-term upside.

The relationships on record — concise, source-backed summaries

Alnylam Pharmaceuticals Inc. (FY2024)

Silence recorded $0.1 million in royalty income from Alnylam during FY2024, indicating a modest royalty stream tied to partner product sales. This is reported in Silence Therapeutics’ 2024 Form 10‑K.

Source: Silence Therapeutics 2024 10‑K (royalty income disclosure, FY2024).

Mallinckrodt plc — PR Newswire announcement (FY2019)

Mallinckrodt obtained an exclusive worldwide license for Silence's complement C3 asset SLN500 with options for additional assets under a 2019 collaboration, reflecting a deal that granted Mallinckrodt development and commercialization rights. The collaboration was publicized via a PR Newswire release in 2019.

Source: PR Newswire release on Mallinckrodt–Silence collaboration (2019).

AstraZeneca — earnings call mention (2024 Q4)

Silence announced that its third siRNA from the GOLD platform entered the clinic in 2024 under an AstraZeneca collaboration, signaling ongoing, active clinical-stage work conducted with a major strategic partner. This was stated on Silence’s Q4 2024 earnings call.

Source: Silence Therapeutics Q4 2024 earnings call (clinical entry disclosure).

AstraZeneca — coverage noting FY2026 revenue impact

Public commentary on FY2026 results noted that revenue declined as fewer AstraZeneca milestones were recognized, implying that AstraZeneca milestone timing materially affects Silence’s short-term revenue. This analysis was reported in a FY2026 news summary.

Source: TradingView reporting on Silence Therapeutics FY2026 revenue commentary (FY2026).

Hansoh — platform deal terms (FY2021)

As disclosed in a 2021 company communication, Hansoh made a $16 million upfront payment and agreed to up to $1.3 billion in milestones plus tiered royalties for certain licensed programs, illustrating the large upside potential embedded in an earlier collaboration. This was summarized in a GlobeNewswire release in 2021.

Source: GlobeNewswire release on Hansoh collaboration terms (2021).

Hansoh — FY2026 revenue commentary

Analysts noted in FY2026 that revenue fell sharply after Hansoh-related activity completed, reinforcing that the Hansoh collaboration produced significant but finite revenue tied to discrete obligations and milestones. This observation was reported alongside FY2026 results.

Source: TradingView reporting on Silence Therapeutics FY2026 revenue (FY2026).

Hansoh Pharma — earnings call reference (2024 Q4)

On the Q4 2024 earnings call, Silence stated it retained global rights to three targets after concluding the Hansoh collaboration, indicating that program termination returned specific assets or rights to Silence and that those retained targets remain company assets for future partnering or internal development.

Source: Silence Therapeutics Q4 2024 earnings call (FY2024 Q4).

What the contractual constraints tell investors about operational risk

The company-level operating signals from Silence’s contracts and disclosures communicate a clear operating model:

• Contract type: licensing is core. Silence routinely out-licenses IP (explicitly to AstraZeneca), confirming the firm’s role as an originator and licensor of siRNA chemistry and candidates.
• Global footprint for partner rights. Several agreements allocate exclusive worldwide rights (with regional carve-outs in some cases), which accelerates partner-led commercialization but concentrates Silence’s upside into milestone/royalty streams.
• Role mix: seller and licensor, not a commercial seller. Silence is primarily a seller of development rights and platform services; revenue recognition follows completion of agreed services or achievement of milestones.
• Event-driven revenue and spend bands. The company recognized a material one-off of $24.6 million in 2024 related to the Hansoh Collaboration, consistent with a spend/milestone band in the $10m–$100m range for discrete collaboration receipts.
• Maturity and termination are part of the lifecycle. Mallinckrodt and Hansoh both concluded commitments, demonstrating program termination as a recurring outcome that reshapes future revenue profiles.

These constraints combine to create high upside tied to successful partner-driven commercialization and high downside from terminated or underperforming collaborations.

Investment implications and what to monitor next

Silence is a pure-play partner-dependent RNAi developer. Key investment considerations:

• Revenue volatility is structural. Expect lumpy income as milestones hit or collaborations complete.
• Clinical progress with AstraZeneca is the most material near-term operational signal. Clinical entries and readouts under that collaboration will drive re-rating events.
• Terminations free up assets but remove near-term revenue. The conclusion of Mallinckrodt and Hansoh obligations has reduced recurring collaboration income but returned specific targets to Silence.
• Small royalty streams are real but immaterial today. Royalty receipts such as the $0.1 million from Alnylam show long-term upside but not near-term revenue support.

For a focused partner-risk analysis and up-to-date exposure mapping, see https://nullexposure.com/.

Practical watchlist for operators and partners

Operators and corporate partners should track: milestone schedules from AstraZeneca and Hansoh-derived assets, any re-licensing or internal development decisions on retained targets, and the cadence of milestone recognitions in quarterly filings. These items directly affect cash runway and strategic optionality.

Bottom line

Silence Therapeutics is a partnership-first RNAi developer whose value is driven by licensing economics, milestone timing, and partner execution. Investors should price in uneven revenue flows, watch AstraZeneca clinical progress closely, and treat past terminations as both a risk mitigation event and a source of future optionality through retained rights. For deeper partner-level exposure analysis and monitoring tools, visit https://nullexposure.com/.

Bold takeaway: SLN’s valuation is fundamentally event-driven — clinical and milestone catalysts under large partner collaborations determine near-term cash generation and long-term upside.